Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lung cancer in the elderly.

Cesare Gridelli1, Corey Langer, Paolo Maione

  • 1Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy. cgridelli@libero.it

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|May 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Inflammatory biomarkers in type 1 diabetes.

Frontiers in endocrinology·2026
Same author

The transcription factor AP-1 regulates the catalase family and oxidative stress adaptation in the dermatophyte Trichophyton rubrum.

Scientific reports·2026
Same author

Effect of Different Types of Whole Dietary Pulses on Established Therapeutic Lipid Targets for Cardiovascular Risk Reduction: An Updated Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials.

Journal of the American Heart Association·2026
Same author

CRISPR screen uncovers SLC26A2 as a modulator of tungsten toxicity in endochondral ossification.

Environmental research·2026
Same author

Genetic Skeletal Disorders with Defects in Glycosaminoglycan Biosynthesis.

Molecular syndromology·2026
Same author

Collagen hybridizing peptide to target in vivo misfolded collagen in OI zebrafish.

Scientific reports·2026

Treatment for elderly lung cancer patients requires careful consideration due to comorbidities. While some therapies show similar efficacy to younger patients, elderly individuals face higher toxicity risks, necessitating individualized approaches.

Area of Science:

  • Geriatric Oncology
  • Thoracic Malignancies
  • Evidence-Based Medicine

Background:

  • Elderly patients present unique challenges in cancer treatment selection due to comorbidities.
  • Lung cancer is a significant health concern in the aging population.

Purpose of the Study:

  • To review and evaluate the therapeutic outcomes for elderly patients diagnosed with lung cancer.
  • To identify treatment strategies that balance efficacy and toxicity in older adults.

Main Methods:

  • Systematic review of existing literature on lung cancer treatment in the elderly.
  • Analysis of retrospective data and available evidence-based guidelines.

Main Results:

  • Adjuvant chemotherapy benefits in early non-small-cell lung cancer (NSCLC) may not directly apply to the elderly due to increased toxicity.

Related Experiment Videos

  • Locally advanced NSCLC treated with chemoradiotherapy shows similar efficacy in older and younger patients, but with higher toxicity.
  • For advanced NSCLC, single-agent chemotherapy is standard for non-selected elderly patients, while fit elderly patients may benefit from platinum-based combinations with acceptable toxicity.
  • In small-cell lung cancer (SCLC), sequential chemoradiotherapy is less toxic than concurrent approaches, and prophylactic cranial irradiation should be avoided in patients with cognitive impairment.

    • Conclusions:

    • Prospective, elderly-specific trials are lacking for most lung cancer types, except advanced NSCLC.
    • Fit elderly patients often experience outcomes comparable to younger individuals, though they are more prone to adverse effects.
    • Treatment decisions for elderly lung cancer patients require careful risk-benefit assessment, considering individual patient factors and available evidence.